Sugi Predict

Sugi Predict / Compounds / SCHEMBL1004754

SCHEMBL1004754

SCHEMBL1004754

O/C(=C(/O)c1cccc(O)c1O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 6/20 0.46
▸ ALDH1A1 P00352 6/20 0.46
▸ HSD17B10 Q99714 4/20 0.46
▸ CA2 P00918 3/20 0.46
▸ LMNA P02545 3/20 0.46
▸ ALOX15 P16050 3/20 0.46
▸ CA1 P00915 2/20 0.46
▸ CA6 P23280 2/20 0.46
▸ EGFR P00533 2/20 0.46
▸ FYN P06241 2/20 0.46
▸ MMP9 P14780 2/20 0.46
▸ RECQL P46063 2/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ ADAMTS4 O75173 1/20 0.46
▸ MMP2 P08253 1/20 0.46
▸ MMP8 P22894 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ MMP12 P39900 1/20 0.46
▸ ADAMTS5 Q9UNA0 1/20 0.46
▸ KDM4E B2RXH2 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL308224 1.00 HPGD (0.46) HPGDALDH1A1HSD17B10CA2LMNA
SCHEMBL3237526 0.87 SELL (0.50) HPGDALDH1A1HSD17B10CA2LMNA
SCHEMBL9087266 0.87 SELL (0.50) HPGDALDH1A1HSD17B10CA2LMNA
SCHEMBL1357094 0.84 HPGD (0.52) HPGDALDH1A1HSD17B10CA2LMNA
SCHEMBL21685 0.84 HPGD (0.52) HPGDALDH1A1HSD17B10CA2LMNA
SCHEMBL2814415 0.79 ALDH1A1 (0.52) HPGDALDH1A1HSD17B10CA2LMNA
SCHEMBL1823581 0.78 ALDH1A1 (0.46) HPGDALDH1A1HSD17B10CA2LMNA
SCHEMBL30489259 0.78 HPGD (0.46) HPGDALDH1A1HSD17B10CA2LMNA
SCHEMBL25377096 0.77 HPGD (0.44) HPGDALDH1A1HSD17B10CA2LMNA
SCHEMBL147459 0.77 GAA (0.58) HPGDALDH1A1HSD17B10CA2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270651-A1 DETECTION OF MET AMPLIFICATION TO PREDICT RESPONSIVENESS OF CANCER TO DRUGS THE GENERAL HOSPITAL CORPORATION (US) 2025-08-28 — — US disclosed
US-11786481-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2023-10-17 — — US disclosed
US-11723449-B2 Artificial intelligence (AI) and augmented reality (AR) enhanced personal care devices/apparatuses MAZED SAYEEDA (US) 2023-08-15 — — US disclosed
US-20200305587-A1 Artificial intelligence (AI) and augmented reality (AR) enhanced personal care devices/apparatuses MAZED SAYEEDA (US) 2020-10-01 — — US disclosed
US-10100029-B2 Combretastatin analogs BIOVENTURES, LLC (US) 2018-10-16 — — US disclosed
US-20180118710-A1 COMBRETASTATIN ANALOGS BIOVENTURES, LLC 2018-05-03 — — US disclosed
US-9884842-B2 Combretastatin analogs BIOVENTURES, LLC (US) 2018-02-06 — — US disclosed
US-20160296477-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2016-10-13 — — US disclosed
US-20160068506-A1 COMBRETASTATIN ANALOGS BIOVENTURES, LLC 2016-03-10 — — US disclosed
EP-2986596-A2 COMBRETASTATIN ANALOGS The Board of Trustees of the University of Arkansas (US) 2016-02-24 — — EP disclosed
WO-2011011065-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2011-01-27 — — WO disclosed
US-7803559-B1 Protein aggregation regulators THE REGENTS OF THE UNIVERSITY OF CA (US) 2010-09-28 — — US disclosed
WO-2010087983-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2010-08-05 — — WO disclosed
US-20100069619-A1 STILBENE DERIVATIVES FOR ADP-RIBOSYL CYCLASE INHIBITORS INDUSTRIAL COOPERATION FOUNDATION CHONBUK NATIONAL UNIVERSITY (KR) 2010-03-18 — — US disclosed
US-20060292652-A1 Substrate detection assay ELIXIR PHARMACEUTICALS, INC. 2006-12-28 — — US disclosed
WO-2006108048-A1 METHOD FOR PREDICTING RESPONSIVENESS TO DRUGS THE GENERAL HOSPITAL CORPORATION (US) 2006-10-12 — — WO disclosed
EP-1156775-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2006-05-17 — — EP disclosed
US-20060084135-A1 Compositions for manipulating the lifespan and stress response of cells and organisms BIOMOL INTERNATIONAL, INC. 2006-04-20 — — US disclosed
EP-1156775-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2001-11-28 — — EP disclosed
WO-2000050002-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069619-A1 STILBENE DERIVATIVES FOR ADP-RIBOSYL CYCLASE INHIBITORS CD38, ADPRS, PARP11 HPGD 450/4885ALDH1A1 1584/4885HSD17B10 1485/4885
US-11786481-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB HPGD 3312/4885ALDH1A1 2877/4885HSD17B10 2278/4885
US-20160296477-A1 Formulation and Process for Modulating Wound Healing SQSTM1, ATG7, TFEB HPGD 3475/4885ALDH1A1 2491/4885HSD17B10 2347/4885
US-20180118710-A1 COMBRETASTATIN ANALOGS HDAC6, HDAC11, HDAC5 HPGD 1255/4885ALDH1A1 2977/4885HSD17B10 870/4885
US-10100029-B2 Combretastatin analogs HDAC6, HDAC11, HDAC5 HPGD 1255/4885ALDH1A1 2977/4885HSD17B10 870/4885
US-20160068506-A1 COMBRETASTATIN ANALOGS HDAC6, HDAC11, HDAC5 HPGD 1255/4885ALDH1A1 2977/4885HSD17B10 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.